Press Releases
Date Title and Summary View
Jul 28, 2014 SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial results for the second quarter of 2014 after the NASDAQ Market closes on Thursday, July 31, 2014 at 4:30 p.m. ET. Conference call and webcast details: ...
Jul 28, 2014 SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted IMBRUVICA® (ibrutinib) regular (full) approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and for the treatment...
Jul 25, 2014 SUNNYVALE, Calif., July 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA® (ibrutinib) in the European Union. IMBRUV...
Jun 9, 2014 SUNNYVALE, Calif., June 9, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphoc...
May 31, 2014 SUNNYVALE, Calif., May 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA®(ibrutinib) in combination with the anti-CD20 antibody, ofatumumab, showed a Kaplan Meier estimate of continued clinical response at 18 months of 82.5% in heavily pre-treated patients with chronic lymphoma leukemia (CLL), small lym...
May 31, 2014 SUNNYVALE, Calif., May 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA® (ibrutinib) will be featured in an oral presentation highlighting long-term responses to treatment, with up to three years of follow up in 132 patients with treatment naive or relapsed/refractory chronic lymphocytic leukemia or s...
May 31, 2014 SUNNYVALE, Calif., May 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced trial results of the first Phase III study (RESONATE, PCYC-1112-CA), a head-to-head comparison of IMBRUVICA® (ibrutinib) versus ofatumumab in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). P...
May 20, 2014 SUNNYVALE, Calif., May 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) is pleased to announce that Gregory R. Wade has joined the company as Executive Vice President of Business Development.   In his position, Greg will further establish the Business Development department and lead all Business Development and Competitiv...
May 14, 2014 SUNNYVALE, Calif., May 14, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced IMBRUVICA® (ibrutinib) will be featured in ten abstracts, including both company-sponsored research studies and investigator-sponsored studies. Preliminary data from these abstracts about IMBRUVICA is available as of today on the website of the A...
May 2, 2014 SUNNYVALE, Calif., May 2, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31, 2014. Financial Results for the Quarter Ended March 31, 2014 GAAP and Non-GAAP net income (loss) Non-GAAP net income reported for the quarter...
1
... NextLast
Add to Briefcase = add release to Briefcase